Search results | onyx


Partnering Agreements with Onyx Pharmaceuticals

The Partnering Agreements with Onyx Pharmaceuticals report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.


Onyx Pharmaceuticals: Oncology specialists and a subsidiary of Amgen

Onyx Pharmaceuticals is a biotechnology company based in San Francisco developing therapies for the treatment of people living with cancer.

Onyx Pharmaceuticals: M&A activity 2009-2014

Onyx Pharmaceuticals purchased Proteolix in October 2009 for a deal valued at $851 million. Proteolix was a privately owned biopharmaceutical company focussed in hematological malignancies and solid tumors.

Onyx Pharmaceuticals: Partnering activity 2009-2014

Onyx Pharmaceuticals is a subsidiary of Amgen, based in San Francisco, California.

Dealtalk: Amgen said to push for lower Onyx price amid data dispute

Amgen is pushing to pay less than the $130 a share it offered this month for Onyx Pharmaceuticals after failing to obtain requested clinical trial data, according to dealtalk.

Onyx provides drug trial data to potential bidders

Onyx Pharmaceuticals has given potential buyers, including Amgen, access to trial data on its new cancer drug, removing a key hurdle that was holding up deal talks, according to dealtalk.

Dealtalk: Amgen, Onyx huddle on $9.5bn deal as other bidders fall away

In dealtalk, Amgen is closing in on a deal for Onyx Pharmaceuticals.

Dealtalk: Amgen Said to Boost Onyx Pharmaceuticals Bid to $130 a Share

Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to dealtalk.

Dealtalk: AstraZeneca, Pfizer, Novartis Among Suitors for Onyx Pharmaceuticals

In dealtalk, AstraZeneca , Pfizer. and Novartis are among the suitors preparing bids for Onyx Pharmaceuticals.

Dealtalk: Pfizer backs off from Onyx bid

Pfizer decided not to pursue a bid for Onyx Pharmaceuticals this week, according to two people familiar with the matter, leaving Amgen in the front position to buy the cancer drugmaker

Dealtalk: Initial takeover bids for Onyx Pharmaceuticals seen as soon as this week

Onyx Pharmaceuticals is expected to receive initial takeover bids as soon as this week after attracting interest from a few drugmakers.


Sorry, your search returned no results.


Amgen in M&A deals with Onyx Pharmaceuticals for $10.4 billion acquisition

Amgen agreed to M&A deals for the acquisition of Onyx Pharmaceuticals for about $10.4 billion in cash to gain access to the company’s three anticancer treatments.

Biotech rumor mill: Amgen Talks to Buy Onyx Said to Stall on Drug Trial Data

In the biotech rumor mill, buyout talks over Amgen’s proposed takeover of Onyx Pharmaceuticals are held up.

Dealtalk: Onyx Pharmaceuticals Potential Sale Involves Multiple Parties

Onyx Pharmaceuticals, the big biotech company said to have rebuffed an initial takeover bid from Amgen, is involved with several potential purchasers, according to dealtalk.

Onyx Pharmaceuticals big biotech deals IDIS Pharma for Multiple Myeloma partnership

Onyx Pharmaceuticals, a big biotech company, has entered pharma deals with IDIS Pharma for Multiple Myeloma treatment.

Onyx at High Seen Poised to Reap 40% More in M&A Takeover

Onyx Pharmaceuticals, which surged to a record sales, is poised to hand shareholders 40 percent more after a regulatory panel’s support for a cancer treatment heightened its allure as a M&A takeover target

M&A: Onyx Pharmaceuticals Shares Rally Amid Rumor of Bayer Acquisition

Drug developer Onyx Pharmaceuticals Inc.’s stock closed up 9 percent on rumors that longtime partner Bayer AG will soon close a M&A deal to buy the South San Francisco biotech company

Onyx CFO says experimental medicines make drugmaker ‘attractive’ purchase

Onyx Pharmaceuticals Inc.,  the developer of kidney cancer drug Nexavar, is an attractive target for acquirers because it may receive regulatory approvals for several new treatments during the next year, Chief Financial Officer Matt Fust said.

Onyx bows out of $550M JAK2 collaboration with S BIO

Onyx Pharmaceuticals has bowed out of its $550 million collaboration deal covering two JAK2 inhibitor programs in development at Singapore’s S BIO.

Onyx snags $339 Japan deal for Phase III cancer med

Onyx’s $851 million deal to buy out Proteolix and its potential blockbuster cancer drug is returning some handsome rewards this morning.

Calithera Biosciences seeks IPO financing for $80 million

Cancer drug developer Calithera Biosciences Inc. is seeking $80 million through an initial public offering financing, the company said in a U.S. Securities and Exchange Commission filing Monday